These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Surgery versus SABR for resectable non-small-cell lung cancer. Zhang L; Tian J; Wang C Lancet Oncol; 2015 Aug; 16(8):e371-2. PubMed ID: 26248837 [No Abstract] [Full Text] [Related]
5. Surgery versus SABR for resectable non-small-cell lung cancer. Cao C; D'Amico T; Demmy T; Dunning J; Gossot D; Hansen H; He J; Jheon S; Petersen RH; Sihoe A; Swanson S; Walker W; Yan TD; Lancet Oncol; 2015 Aug; 16(8):e370-1. PubMed ID: 26248836 [No Abstract] [Full Text] [Related]
6. Surgery versus SABR for resectable non-small-cell lung cancer - Authors' reply. Chang JY; Senan S; Smit EF; Roth JA Lancet Oncol; 2015 Aug; 16(8):e374-5. PubMed ID: 26248841 [No Abstract] [Full Text] [Related]
7. SABR vs surgery for NSCLC in the media. Rice D; Sepesi B; Heymach J; Swisher S; Vaporciyan A Lancet Oncol; 2015 Sep; 16(9):e422. PubMed ID: 26370343 [No Abstract] [Full Text] [Related]
8. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Chang JY; Senan S; Paul MA; Mehran RJ; Louie AV; Balter P; Groen HJ; McRae SE; Widder J; Feng L; van den Borne BE; Munsell MF; Hurkmans C; Berry DA; van Werkhoven E; Kresl JJ; Dingemans AM; Dawood O; Haasbeek CJ; Carpenter LS; De Jaeger K; Komaki R; Slotman BJ; Smit EF; Roth JA Lancet Oncol; 2015 Jun; 16(6):630-7. PubMed ID: 25981812 [TBL] [Abstract][Full Text] [Related]
9. Surgery versus SABR for resectable non-small-cell lung cancer. Dearman C; van As N; Crellin A; Slevin N; Sharma RA Lancet Oncol; 2015 Aug; 16(8):e373-4. PubMed ID: 26248840 [No Abstract] [Full Text] [Related]
10. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer. Katz MS; Husain ZA Lancet Oncol; 2016 Feb; 17(2):e41-e42. PubMed ID: 26868347 [No Abstract] [Full Text] [Related]
11. Lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? Meyers BF; Puri V; Broderick SR; Samson P; Keogan K; Crabtree TD J Thorac Cardiovasc Surg; 2015 Sep; 150(3):468-71. PubMed ID: 26259993 [No Abstract] [Full Text] [Related]
12. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply. Chang JY; Senan S; Smit EF; Roth JA Lancet Oncol; 2016 Feb; 17(2):e42-e43. PubMed ID: 26868349 [No Abstract] [Full Text] [Related]
13. [Randomised comparison of stereotactic body radiotherapy versus lobectomy in stage I NSCLC--level I evidence at last?]. Guckenberger M; Andratschke N Strahlenther Onkol; 2015 Dec; 191(12):988-90. PubMed ID: 26459463 [No Abstract] [Full Text] [Related]
14. Do we know bad science when we see it? Jones DR J Thorac Cardiovasc Surg; 2015 Sep; 150(3):472-3. PubMed ID: 26254751 [No Abstract] [Full Text] [Related]
15. Local Therapy for Limited Metastatic Non-Small Cell Lung Cancer: What Are the Options and Is There a Benefit? Iyengar P; Lau S; Donington JS; Suh RD Am Soc Clin Oncol Educ Book; 2016; 35():e460-7. PubMed ID: 27249754 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360 [TBL] [Abstract][Full Text] [Related]
17. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome. Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556 [TBL] [Abstract][Full Text] [Related]
18. If at First You Don't Succeed-Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer. Owen D; Siva S; Salama JK; Robinson C; Kruser TJ; Giuliani M Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):5-9. PubMed ID: 35964631 [No Abstract] [Full Text] [Related]
19. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Paix A; Noel G; Falcoz PE; Levy P Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]